Great Basin Scientific, Inc. (NASDAQ:GBSN) revealed on Thursday that it will showcase its own cost-efficient, sample-to-result solution at the American Society for Microbiology (ASM) Microbe 2016, which is scheduled from June 17 to 20 at Massachusetts, in its efforts to give small-to-medium hospitals a deeper understanding on how to minimize costs while improving efficiency for better outcomes.

Great Basin Scientific Exhibit

Sandra Nielsen, Great Basin Scientific Sales and Marketing, Human Resources Senior Vice President (SVP), reiterated the company’s excitement to present its diagnostic platform at one of the most prestigious conferences in the world.

Great Basin Scientific exhibit will provide attendees with one-on-one demonstrations. They can also ask for a meeting schedule with the company’s Product and Sales team leaders.

Aside from the exhibit, the Scientific Program has also chosen posters that show the platform’s actual outcomes as provided by third party researchers.

Nielsen emphasized that the massive consumer growth and overwhelming user feedback indicate a strong position for Great Basin Scientific’s innovative offerings.

ASM Microbe 2016

ASM Microbe 2016 is a primary integration of ASM’s two main events, General Meeting and ICAAC. The event hopes to bring the most cutting-edge and the most innovative microbial science advancements globally. It also provides a forum that showcases the entire microbiology realm— from basic science to the most complex application.

Stool Bacterial Pathogens Panel Clinical Trial

In other news, the molecular diagnostics company had also revealed earlier this week that it has launched a clinical trial for the Stool Bacterial Pathogens Panel, the company’s second multiplex panel. Also, this marks the second start of five clinical trials planned for the year.

Basically, the Stool Bacterial Pathogens Panel will target the nucleic acids of the Campylobacter species, E. coli O157 serotype, Salmonella species, Shiga toxin-producing E. coli, and Shigella species.

Ryan Ashton, Great Basin Scientific Co-Founder and CEO, explained that the beginning of this clinical trial signifies the company’s commitment to fulfilling its goals. Ashton added that Great Basin Scientific is delighted with its accomplishments so far in the year. In line with this, the company is confident that it can carry out its long-term goals with its compelling research and development (R&D) team.